Better-than-Expected Label for BMS' Ipilimumab in Melanoma
By Jennifer Boggs
Monday, March 28, 2011
Bristol-Myers Squibb Co. is planning a quick rollout of ipilimumab following its Friday approval as the first drug to demonstrate improvement in overall survival in metastatic melanoma.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.